Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window

Neurobiology of Disease

Volumn 49, Issue 1, 2013, Pages 177-189

  Lanzillotta, Annamaria ^a   Pignataro, Giuseppe ^b   Branca, Caterina ^a   Cuomo, Ornella ^b   Sarnico, Ilenia ^a   Benarese, Marina ^a   Annunziato, Lucio ^b,d   Spano, PierFranco ^a,c   Pizzi, Marina ^a,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c IRCCS SAN CAMILLO HOSPITAL   (Italy)

^d IRCCS SDN   (Italy)

Author keywords

HDAC inhibitors; MCAO; OGD; RelA acetylation

Indexed keywords

BIM PROTEIN; ENTINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE H3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN BCL XL; RESVERATROL; SIRTUIN 1; TRANSCRIPTION FACTOR RELA; BENZAMIDE DERIVATIVE; GLUCOSE; HISTONE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUROPROTECTIVE AGENT; PYRIDINE DERIVATIVE; RELA PROTEIN, MOUSE; SIRT1 PROTEIN, MOUSE; STILBENE DERIVATIVE;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN INFARCTION; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN NERVE CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; ANIMAL; BRAIN; C57BL MOUSE; CELL HYPOXIA; CEREBRAL ARTERY DISEASE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETIC EPIGENESIS; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY;

ACETYLATION; ANIMALS; BENZAMIDES; BRAIN; BRAIN ISCHEMIA; CELL HYPOXIA; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; GLUCOSE; HISTONE DEACETYLASE INHIBITORS; HISTONES; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS; NF-KAPPA B; PYRIDINES; SIRTUIN 1; STILBENES; TRANSCRIPTION FACTOR RELA;

EID: 84866564556     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.08.018     Document Type: Article

References (53)

1. Agrawal M., Kumar V., Kashyap M.P., Khanna V.K., Randhawa G.S., Pant A.B. Ischemic insult induced apoptotic changes in PC12 cells: protection by trans resveratrol. Eur. J. Pharmacol. 2011, 666:5-11.
2. Asensi M., Medina I., Ortega A., Carretero J., Baño M.C., Obrador E., et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 2002, 33:387-398.
3. Ashburner B.P., Westerheide S.D., Baldwin A.S. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 2001, 21:7065-7077.
4. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5:493-506.
5. Bederson J.B., Pitts L.H., Germano S.M., Nishimura M.C., Davis R.L., Bartkowski H.M. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986, 17:1304-1308.
6. Blackwell L., Norris J., Suto C.M., Janzen W.P. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci. 2008, 82:1050-1058.
7. Boutillier A.L., Trinh E., Loeffler J.P. Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J. Neurochem. 2003, 84:814-828.
8. Bramlett H.M., Dietrich W.D. Pathophysiology of cerebral ischemia and brain trauma: similarities and differences. J. Cereb. Blood Flow Metab. 2004, 24:133-150.
9. Calvani M., Arrigoni-Martelli E. Attenuation by acetyl-l-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int. J. Tissue React. 1999, 21:1-6.
10. Chen L.F., Greene W.C. Shaping the nuclear action of NF-kappaB. Nat. Rev. Mol. Cell Biol. 2004, 5:392-401.
11. Clark W.M., Lessov N.S., Dixon M.P., Eckenstein F. Monofilament intraluminal middle cerebral artery occlusion in the mouse. Neurol. Res. 1997, 19:641-648.
12. Culmsee C., Monnig J., Kemp B.E., Mattson M.P. AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J. Mol. Neurosci. 2001, 17:45-58.
13. Fang M.C., Cutler D.M., Rosen A.B. Trends in thrombolytic use for ischemic stroke in the United States. J. Hosp. Med. 2010, 5:406-409.
14. Faraco G., Pancani T., Formentini L., Mascagni P., Fossati G., Leoni F., et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 2006, 70:1876-1884.
15. Gan Y., Shen Y.H., Wang J., Wang X., Utama B., Wang J., et al. Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase. J. Biol. Chem. 2005, 280:16467-16475.
16. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 2009, 10:32-42.
17. Hahnen E., Hauke J., Trankle C., Eyupoglu I.Y., Wirth B., Blumcke I. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin. Investig. Drugs 2008, 17:169-184.
18. Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M., et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005, 2:9-19.
19. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
20. Inta I., Paxian S., Maegele I., Zhang W., Pizzi M., Spano P., et al. Bim and Noxa are candidates to mediate the deleterious effect of the NF-kappa B subunit RelA in cerebral ischemia. J. Neurosci. 2006, 26:12896-12903.
21. Jin K., Mao X.O., Simon R.P., Greenberg D.A. Cyclic AMP response element binding protein (CREB) and CREB binding protein (CBP) in global cerebral ischemia. J. Mol. Neurosci. 2001, 16:49-56.
22. Johnson C.A., White D.A., Lavender J.S., O'Neill L.P., Turner B.M. Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. J. Biol. Chem. 2002, 277:9590-9597.
23. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 2008, 409:581-589.
24. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 2007, 321:892-901.
25. Kim H.J., Leeds P., Chuang D.M. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J. Neurochem. 2009, 110:1226-1240.
26. Langley B., D'Annibale M.A., Suh K., Ayoub I., Tolhurst A., Bastan B., et al. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J. Neurosci. 2008, 28:163-176.
27. Lanzillotta A., Sarnico I., Ingrassia R., Boroni F., Branca C., Benarese M., et al. The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury. Cell Death Dis. 2010, 1:e96.
28. Lees K.R., Bluhmki E., von Kummer R., Brott T.G., Toni D., Grotta J.C., et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010, 375:1695-1703.
29. Leker R.R., Shohami E., Constantini S. Experimental models of head trauma. Acta Neurochir. Suppl. 2002, 83:49-54.
30. Li H., Yan Z., Zhu J., Yang J., He J. Neuroprotective effects of resveratrol on ischemic injury mediated by improving brain energy metabolism and alleviating oxidative stress in rats. Neuropharmacology 2011, 60:252-258.
31. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., et al. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010, 121:948-954.
32. Lutz M., Burke L.J., Barreto G., Goeman F., Greb H., Arnold R., et al. Transcriptional repression by the insulator protein CTCF involves histone deacetylases. Nucleic Acids Res. 2000, 28:1707-1713.
33. Martin E., Rosenthal R.E., Fiskum G. Pyruvate dehydrogenase complex: metabolic link to ischemic brain injury and target of oxidative stress. J. Neurosci. Res. 2005, 79:240-247.
34. Morris K.C., Lin H.W., Thompson J.W., Perez-Pinzon M.A. Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J. Cereb. Blood Flow Metab. 2011, 31:1003-1019.
35. Pignataro G., Meller R., Inoue K., Ordonez A.N., Ashley M.D., Xiong Z., et al. In vivo and in vitro characterization of a novel neuroprotective strategy for stroke: ischemic postconditioning. J. Cereb. Blood Flow Metab. 2008, 28:232-241.
36. Pizzi M., Sarnico I., Boroni F., Benarese M., Steimberg N., Mazzoleni G., et al. NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. Cell Death Differ. 2005, 12:761-772.
37. Raval A.P., Dave K.R., Pérez-Pinzón M.A. Resveratrol mimics ischemic preconditioning in the brain. J. Cereb. Blood Flow Metab. 2006, 26:1141-1147.
38. Ren J., Fan C., Chen N., Huang J., Yang Q. Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO - 1 in rats. Neurochem. Res. 2011, 36:2352-2362.
39. Robb E.L., Stuart J.A. trans-Resveratrol as a neuroprotectant. Molecules 2010, 15:1196-1212.
40. Rocha S., Campbell K.J., Perkins N.D. p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. Mol. Cell 2003, 12:15-25.
41. Rouaux C., Jokic N., Mbebi C., Boutillier S., Loeffler J.P., Boutillier A.L. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 2003, 22:6537-6549.
42. Ruderman N.B., Xu X.J., Nelson L., Cacicedo J.M., Saha A.K., Lan F., et al. AMPK and SIRT1: a long-standing partnership?. Am. J. Physiol. Endocrinol. Metab. 2010, 298:E751-E760.
43. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 2005, 23:3912-3922.
44. Sarnico I., Lanzillotta A., Boroni F., Benarese M., Alghisi M., Schwaninger M., et al. NF-kappaB p50/RelA and c-Rel-containing dimers: opposite regulators of neuron vulnerability to ischaemia. J. Neurochem. 2009, 108:475-485.
45. Shein N.A., Shohami E. Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries. Mol. Med. 2011, 17:448-456.
46. Simonini M.V., Camargo L.M., Dong E., Maloku E., Veldic M., Costa E., et al. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1587-1592.
47. Smoliga J.M., Baur J.A., Hausenblas H.A. Resveratrol and health - a comprehensive review of human clinical trials. Mol. Nutr. Food Res. 2011, 55:1129-1141.
48. Sweatt J.D. Experience-dependent epigenetic modifications in the CNS. Biol. Psychiatry 2009, 65:191-197.
49. Tan J., Cang S., Ma Y., Petrillo R.L., Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 2010, 3:5.
50. Turnley A.M., Stapleton D., Mann R.J., Witters L.A., Kemp B.E., Bartlett P.F. Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. J. Neurochem. 1999, 72:1707-1716.
51. Wang Y., Liang Y., Vanhoutte P.M. SIRT1 and AMPK in regulating mammalian senescence: a critical review and a working model. FEBS Lett. 2011, 585:986-994.
52. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004, 23:2369-2380.
53. Yu W., Fu Y.C., Wang W. Cellular and molecular effects of resveratrol in health and disease. J. Cell. Biochem. 2012, 113:752-759.